Time to Confirmatory Study Initiation After Accelerated Approval of Cancer and Noncancer Drugs in the US

被引：3
|
作者：
Jazowski, Shelley A. [1 ,5 ]
Vaidya, Avi U. [1 ]
Donohue, Julie M. [2 ]
Dusetzina, Stacie B. [1 ,3 ]
Sachs, Rachel E. [4 ]
机构：
[1] Vanderbilt Univ, Sch Med, Dept Hlth Policy, Nashville, TN USA
[2] Univ Pittsburgh, Sch Publ Hlth, Dept Hlth Policy & Management, Pittsburgh, PA USA
[3] Vanderbilt Ingram Canc Ctr, Nashville, TN USA
[4] Washington Univ St Louis, Sch Law, St Louis, MO USA
[5] Vanderbilt Univ, Sch Med, Dept Hlth Policy, 2525 West End Ave,Ste 1200, Nashville, TN 37203 USA
来源：
JAMA INTERNAL MEDICINE | 2023年 / 183卷 / 07期
基金：
美国医疗保健研究与质量局;
关键词：
D O I：
10.1001/jamainternmed.2023.0777
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
This cross-sectional study examines and compares the time taken from the accelerated approval of cancer and noncancer drugs to the initiation of confirmatory studies in the US.
引用
收藏
页码：737 / 739
页数：3
相关论文
共 50 条
  • [41] Time from US Food and Drug Administration approval to publication of data for cancer drugs: a comparison of first and subsequent approvals
    Lammers, Austin
    Wang, Ruibin
    Cetnar, Jeremy
    Prasad, Vinay
    BLOOD CANCER JOURNAL, 2017, 7
  • [42] Time from US Food and Drug Administration approval to publication of data for cancer drugs: a comparison of first and subsequent approvals
    Austin Lammers
    Ruibin Wang
    Jeremy Cetnar
    Vinay Prasad
    Blood Cancer Journal, 7
  • [43] Accelerated vs regular approval, differences in study characteristics of lung cancer treatments approved by the US Food and Drug Administration
    Ribeiro, Tatiane
    Buss, Lewis
    Ali, Sanni
    Nobre, Moacyr
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 163 - 163
  • [44] Therapeutic Value of Drugs Granted Accelerated Approval or Conditional Marketing Authorization in the US and Europe From 2007 to 2021
    Vokinger, Kerstin N.
    Kesselheim, Aaron S.
    Glaus, Camille E. G.
    Hwang, Thomas J.
    JAMA HEALTH FORUM, 2022, 3 (08): : e222685
  • [45] FDA fails to monitor fast tracked drugs after approval, says US watchdog
    Dyer, Owen
    BMJ-BRITISH MEDICAL JOURNAL, 2016, 352
  • [46] US drugs were granted breakthrough approval on weak evidence, study finds
    Wise, Jacqui
    BMJ-BRITISH MEDICAL JOURNAL, 2018, 362
  • [47] Spending by the Centers for Medicare & Medicaid Services Before and After Confirmation of Benefit for Drugs Granted US Food and Drug Administration Accelerated Approval, 2012 to 2017
    Skydel, Joshua J.
    Egilman, Alexander C.
    Wallach, Joshua D.
    Ramachandran, Reshma
    Gupta, Ravi
    Ross, Joseph S.
    JAMA HEALTH FORUM, 2022, 3 (05):
  • [48] Comparison of novel oncology drugs that received dual approval from the US accelerated approval and EU conditional marketing authorisation pathways, 2006-2021: a cross-sectional study
    Xie, Jinping
    Li, Jinlian
    Liu, Yue
    Wang, Haoyang
    Wang, Yifei
    Yang, Yifan
    Chen, Yi
    Jiang, Rong
    Shao, Rong
    BMJ OPEN, 2023, 13 (06):
  • [49] Estimated Medicare Spending on Cancer Drug Indications With a Confirmed Lack of Clinical Benefit After US Food and Drug Administration Accelerated Approval
    Shahzad, Mahnum
    Naci, Huseyin
    Wagner, Anita K.
    JAMA INTERNAL MEDICINE, 2021, 181 (12) : 1673 - 1675
  • [50] Alcohol use and prostate cancer in US whites: No association in a confirmatory study
    Lumey, LH
    Pittman, B
    Wynder, EL
    PROSTATE, 1998, 36 (04): : 250 - 255
12345